Please login to the form below

Not currently logged in
Email:
Password:

SGLT inhibitor

This page shows the latest SGLT inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

SGLT2 inhibitor failed to significantly reduce the number of patients who experienced organ failure or died compared to placebo. ... AstraZeneca’s (AZ) SGLT-2 inhibitor Farxiga showed no significant benefit for hospitalised COVID-19 patients, according

Latest news

  • Sanofi exits Zynquista alliance with Lexicon Sanofi exits Zynquista alliance with Lexicon

    The drug is a dual inhibitor of SGLT1 and SGLT2 and was thought to work by reducing glucose absorption in the gastrointestinal tract and glucose reabsorption by the kidneys, as well ... Issues surrounding the higher rate of diabetic ketoacidosis (DKA) in

  • NICE recommends MSD’s diabetes drug Steglatro NICE recommends MSD’s diabetes drug Steglatro

    drug. Steglatro is one of the competitors in the sodium-glucose cotransporter-2 (SGLT-2) inhibitor drugs, which are now becoming standard therapy in managing type 2 diabetes (T2D) patients in ... In the UK, the treatment is priced at £29.40 for 28 days,

  • The year of the blockbuster The year of the blockbuster

    Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel

  • Novo’s diabetes pill defeats Merck’s Januvia in trial Novo’s diabetes pill defeats Merck’s Januvia in trial

    Comparing oral semaglutide to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), PIONEER 7 investigated the efficacy and safety of the GLP-1 inhibitor in people with type 2 diabetes. ... PIONEER 4 saw the enrolment of 711 people with type 2 diabetes

  • FDA panel backs CV claims for Novo Nordisk's Victoza FDA panel backs CV claims for Novo Nordisk's Victoza

    Victoza is the second drug to get a recommendation for improving cardiovascular outcomes in type 2 diabetics after Eli Lilly and Boehringer Ingelheim's SGLT-2 inhibitor Jardiance (empagliflozin), which had ... Merck &Co failed to win FDA approval for a

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...